Incyte Corporation (NASDAQ:INCY)‘s stock had its “buy” rating reissued by equities research analysts at J P Morgan Chase & Co in a research note issued on Tuesday.

INCY has been the subject of several other reports. BidaskClub downgraded Incyte Corporation from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. BMO Capital Markets dropped their target price on Incyte Corporation from $163.00 to $162.00 and set an “outperform” rating for the company in a research report on Thursday, October 26th. Cowen and Company reaffirmed an “outperform” rating and issued a $130.00 target price on shares of Incyte Corporation in a research report on Monday, July 3rd. Barclays PLC reaffirmed an “overweight” rating and issued a $165.00 target price (down from $180.00) on shares of Incyte Corporation in a research report on Wednesday, August 2nd. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $165.00 target price on shares of Incyte Corporation in a research report on Tuesday, July 4th. Seven analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. Incyte Corporation presently has a consensus rating of “Buy” and a consensus target price of $144.80.

Incyte Corporation (NASDAQ:INCY) traded down 1.00% on Tuesday, hitting $113.10. 1,646,297 shares of the stock were exchanged. Incyte Corporation has a 52-week low of $83.01 and a 52-week high of $153.15. The firm’s market cap is $23.27 billion. The stock’s 50 day moving average price is $115.21 and its 200 day moving average price is $124.22.

Incyte Corporation (NASDAQ:INCY) last issued its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.11. The firm had revenue of $381.50 million for the quarter, compared to analyst estimates of $360.34 million. Incyte Corporation had a negative net margin of 11.77% and a negative return on equity of 21.57%. Incyte Corporation’s revenue was up 41.6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.19 EPS. Equities research analysts forecast that Incyte Corporation will post ($0.82) earnings per share for the current year.

WARNING: This report was first reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/10/31/incyte-corporation-incy-given-buy-rating-at-j-p-morgan-chase-co.html.

In other Incyte Corporation news, EVP Barry P. Flannelly sold 714 shares of the stock in a transaction on Thursday, September 14th. The stock was sold at an average price of $124.25, for a total value of $88,714.50. Following the completion of the transaction, the executive vice president now owns 15,496 shares in the company, valued at $1,925,378. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, President Herve Hoppenot sold 70,502 shares of the stock in a transaction on Monday, September 18th. The stock was sold at an average price of $119.45, for a total value of $8,421,463.90. The disclosure for this sale can be found here. In the last quarter, insiders sold 101,147 shares of company stock valued at $12,615,101. 17.70% of the stock is owned by company insiders.

Large investors have recently added to or reduced their stakes in the business. Thrivent Financial For Lutherans acquired a new stake in Incyte Corporation in the first quarter valued at $865,000. Dimensional Fund Advisors LP lifted its position in Incyte Corporation by 18.1% during the first quarter. Dimensional Fund Advisors LP now owns 464,549 shares of the biopharmaceutical company’s stock worth $62,105,000 after buying an additional 71,111 shares during the period. Highbridge Capital Management LLC lifted its position in Incyte Corporation by 22.5% during the first quarter. Highbridge Capital Management LLC now owns 3,570 shares of the biopharmaceutical company’s stock worth $478,000 after buying an additional 655 shares during the period. AQR Capital Management LLC lifted its position in Incyte Corporation by 1,626.0% during the first quarter. AQR Capital Management LLC now owns 94,928 shares of the biopharmaceutical company’s stock worth $12,689,000 after buying an additional 89,428 shares during the period. Finally, First American Trust FSB purchased a new position in Incyte Corporation during the second quarter worth about $4,768,000. Hedge funds and other institutional investors own 88.85% of the company’s stock.

Incyte Corporation Company Profile

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Analyst Recommendations for Incyte Corporation (NASDAQ:INCY)

Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with MarketBeat.com's FREE daily email newsletter.